Okamoto Yukiko, Takai Shinji, Miyazaki Mizuo
Department of Pharmacology, Osaka Medical College, Takatsuki City, Japan.
J Surg Res. 2002 Oct;107(2):219-22. doi: 10.1006/jsre.2002.6515.
Mast cells are closely related to adhesion formation, while it has been unclear which factor in mast cells plays an important role in the development of adhesion formation. To clarify the role of chymase produced from mast cells in adhesion formation, we investigated the preventive effect of a specific chymase inhibitor, BCEAB, on adhesion formation in a hamster experimental model.
Hamsters were administered orally once daily with 100 mg/kg of BCEAB or placebo from the operated day to 1 week after the operation. The uterus was grasped and denuded by a swab.
One week after the operation, the scores for adhesion formation in the chymase inhibitor-treated group were significantly decreased in comparison with those in the placebo-treated group (placebo-treated group, 2.80 +/- 0.20; chymase inhibitor-treated group 1.60 +/- 0.31: P < 0.01). The chymase activity in the injured uterus was also significantly suppressed in the chymase inhibitor-treated group (placebo-treated group, 17.3 +/- 2.69 mU/mg protein; chymase inhibitor-treated group 9.60 +/- 0.89: P < 0.05). After scraping the utelus, the level of transforming growth factor-beta in the peritoneal fluid was significantly increased in the placebo-treated group, while it was suppressed to 70% by the treatment with BCEAB.
The specific chymase inhibitor BCEAB may be a useful drug for prevention of adhesion formation.
肥大细胞与粘连形成密切相关,然而尚不清楚肥大细胞中的哪种因子在粘连形成的发展中起重要作用。为了阐明肥大细胞产生的糜蛋白酶在粘连形成中的作用,我们在仓鼠实验模型中研究了特异性糜蛋白酶抑制剂BCEAB对粘连形成的预防作用。
从手术当天至术后1周,仓鼠每天口服一次100mg/kg的BCEAB或安慰剂。用拭子抓取并剥离子宫。
术后1周,与安慰剂治疗组相比,糜蛋白酶抑制剂治疗组的粘连形成评分显著降低(安慰剂治疗组,2.80±0.20;糜蛋白酶抑制剂治疗组1.60±0.31:P<0.01)。在糜蛋白酶抑制剂治疗组中,受损子宫中的糜蛋白酶活性也显著受到抑制(安慰剂治疗组,17.3±2.69mU/mg蛋白质;糜蛋白酶抑制剂治疗组9.60±0.89:P<0.05)。刮除子宫后,安慰剂治疗组腹腔液中转化生长因子-β水平显著升高,而用BCEAB治疗可将其抑制至70%。
特异性糜蛋白酶抑制剂BCEAB可能是预防粘连形成的有效药物。